Jan 2 (Reuters) - Hong Kong-headquartered biopharmaceutical company Hutchmed (China) on Wednesday said it will sell stakes in a health subsidiary to GP Health Service Capital and Shanghai Pharmaceuticals for about $608 million.
(Reporting by Kumar Tanishk in Bengaluru; Editing by Cynthia Osterman)
((Tanishk.Kumar@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments